Regeneron, Sanofi Drop After-Hours as Covid-19 Vaccine Trial Halted

By Christiana Sciaudone — Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:)fell 2.6% and Sanofi (PA:)fell 1.7% in after-hours trading Thursday after the companies said phase 3 of their Covid-19 vaccine trial did not meet endpoints and they would halt the U.S. trial.

Kevzara (sarilumab) 400 mg did not meet primary and key secondary endpoints compared to a placebo. Minor positive trends were seen but were not statistically significant, and countered by negative trends in a subgroup of critical patients.

A trial of patients who received a dose of 800 mg of Kevzara was also halted.

A separate Sanofi-led trial outside the U.S. in hospitalized patients with severe and critical Covid-19 using a different dosing regimen is ongoing.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.


Leave a Reply